The best management for any patient with cancer is receiving the most innovative cancer drugs in advanced stages of development. There, the hope and chances to live longer go far beyond the standard protocols:
Keytruda and combination of Keytruda+platinum+5-FU as new first-line standards of care for recurrent or metastatic head and neck squamous cell carcinoma.
About KEYNOTE-048 trial
The phase III KEYNOTE-048 trial examined the efficacy of Keytruda alone, Keytruda + fluorouracil (5-FU) + cisplatin/carboplatin, or the standard of care which is Erbitux + 5-FU + cisplatin or carboplatin (also called the “EXTREME” protocol) as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma. 882 patients with locally incurable recurrent or metastatic head and neck cancer who had no prior systemic therapy in the recurrent or metastatic setting were enrolled.
At the 2019 ASCO Annual Meeting, the biggest oncology congress, the investigators presented the protocol-specified final results of the trial:
NOTE! “CPS” is a type of PD-L1 assessment score and the higher the score, the higher the PD-L1.
In the CPS ≥ 20 population (Highly positive PD-L1)
- Treatment with Keytruda/chemotherapy resulted in a median overall survival of 14.7 months vs 11.0 months with Erbitux/chemotherapy
- The risk of death from the disease during treatment with Keytruda/chemotherapy has decreased by 40% compared to Erbitux/chemotherapy
- The risk for disease progression during treatment with Keytruda/chemotherapy has decreased by 24% compared to Erbitux/chemotherapy
- The overall response rate was 42.9% with Keytruda/chemotherapy vs 38.2% with Erbitux/chemotherapy
- The median duration of response was 7.1 with Keytruda/chemotherapy vs 4.2 months with Erbitux/chemotherapy
In the CPS ≥ 1 population (moderately positive PD-L1)
- The median overall survival was 13.6 months with Keytruda/chemotherapy vs 10.4 months with Erbitux/chemotherapy
- The risk of death from the disease during treatment with Keytruda/chemotherapy has decreased by 35% compared to Erbitux/chemotherapy
- The risk for disease progression during treatment with Keytruda/chemotherapy has decreased by 16% compared to Erbitux/chemotherapy
- The median duration of response was with Keytruda/chemotherapy 6.7 vs 4.3 months with Erbitux/chemotherapy
TRIAL•IN Pharma offers a unique, personalized search for patients with metastatic cancer and malignant brain tumors, which reveals advanced and innovative cancer treatments worldwide and helps to achieve them.
For free service assessment to our service, dial 24/7
+44.2082.426.039 or contact us through our website
Do not give up on life!
